Impact of body mass index on the efficacy of immune combination therapy in metastatic renal cell carcinoma: a multicenter study in Japan.

ABSTRACT:

Background

Renal cell carcinoma (RCC) is a major urologic malignancy worldwide, with obesity recognized as a known risk factor. Interestingly, a higher body mass index (BMI) has been associated with improved outcomes in immunotherapy, a phenomenon termed the "obesity paradox." This study investigates the influence of BMI on the effectiveness of immune combination therapies in Japanese patients with metastatic RCC.

Methods

A retrospective study was conducted on 243 Japanese patients with metastatic RCC who received immune combination therapies between 2018 and 2022. Patients were stratified into two groups: non-overweight/obesity (BMI < 25 kg/m²) and overweight/obesity (BMI ≥ 25 kg/m²). Survival outcomes, including progression-free survival (PFS) and ove

SUBMITTER: Anami T 

PROVIDER: S-EPMC12474707 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature